PT-141

FDA Approved

Bremelanotide

Category
Sexual Health
Aliases
Bremelanotide, Vyleesi
Administration
Subcutaneous injection (approved), Intranasal (research)

Research and regulatory

Development stage

FDA approved June 2019 for HSDD in premenopausal women (Vyleesi).

Legal and regulatory

FDA approved — Vyleesi (bremelanotide).

Side effects

Nausea (40%), flushing, hyperpigmentation